What this means
Researchers plan to randomly assign about 1,500 healthy adults over 50 to a personal program or none. They hope to see lower biological age, but the trial has not yet reported results.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 50 and over · About 1,500 healthy community-dwelling adults over 50 in Israel
- Where
- 1 site
The science
- Registered title
- Sheba Healthspan Research Population (SHARP) Trial - Sheba Longevity Center Diagnostic and Intervention Protocol to Lower Biological Age in Older Adults
- Trial ID
- NCT07596576 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Healthy Aging, Healthspan, Biological Age, Intrinsic Capacity, Immunaging
- What is tested
- healthspan personalized protocol, Control
- Sponsor
- Sheba Medical Center
- Ages
- 50 Years to no maximum
- Dates
- First posted May 19, 2026 · updated May 19, 2026
Registry summary
Background: Population aging is accelerating rapidly in Israel and worldwide, necessitating adaptation of the healthcare system and considering new approaches that serve the needs of older adult populations.
Working hypothesis and aims: We hypothesize that a personalized health and behavior intervention program will decrease the biological age as assessed by several biological aging clocks and improve functional and cognitive performance among older adults.
Methods: We propose to conduct a randomized study among healthy community-dwelling elderly subjects (>50 years old). The study will include an extensive aging assessment and imaging protocol (baseline assessment), including comprehensive physical, functional, sensory, cognitive, and mental assessment. Each participant in the intervention group will receive a personalized intervention program based on an integrative systems approach analysis. In addition, a uniquely developed application will track compliance and monitor physiological data through a provided wearable device. The control group will be assessed at baseline without receiving an intervention program. Each participant will visit the center aging after 6 months for a blood test and after 12 months for a second extensive diagnostic protocol, similar to the baseline assessment protocol. About 1,500 subjects will be recruited to participate in the study.
Expected results: Obtaining data at two points will allow us to examine efficiency and compliance with a personalized intervention program based on integrative systems analysis models. We expect biological age, general well-being, and various clinical and psychosocial outcomes in the intervention group will decrease and improve compared to the control group.
Study importance and relevance: The obtained results may help establish evidence-based healthy aging diagnostics protocols and an effective personalized intervention program that might be applied, with proper modifications, to national healthcare organizations for the general older adult population. In addition, to provides a scientific basis on which policymakers and intervention programs can rely to develop national guidelines for promoting extended health.
Sites (1)
- Sheba Medical Center, Ramat Gan, Tel Aviv, Israel